Agoracom Blog Home

Posts Tagged ‘weed’

North Bud Farms Inc. $NBUD.ca – ‘Game changer’: Health Canada changes cannabis licensing process $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 2:00 PM on Thursday, May 9th, 2019

SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE

—————

‘Game changer’: Health Canada changes cannabis licensing process

By David George-Cosh

Health Canada is changing the way it issues cannabis industry licences in a move that will likely alleviate a bottleneck that observers attribute to a long-running shortage of legal pot in the country.

Effective immediately, the regulator says new applicants seeking to produce, sell or process cannabis must already have a fully built facility. Previously, applicants were only required to make a paper submission.

“This is a game changer,” said Matt Maurer, a cannabis lawyer with Torkin Manes LLP, in a phone interview with BNN Bloomberg.

“We go from a situation where if you wanted to submit an application, you submit your paperwork and you sit and wait to hear back from Health Canada,” he said. “Now you’re asked to build a $30-million to $40-million facility before you even submit your application.”

Health Canada said it is making these changes after reviewing its existing process where more than 70 per cent of applicants whose paperwork was approved over the last three years failed to provide evidence of a having a cannabis facility that meets regulatory requirements.  

“As a result, a significant amount of resources are being used to review applications from entities that are not ready to begin operations, contributing to wait times for more mature applications and an inefficient allocation of resources,” Health Canada said in a release Wednesday.

Industry applicants have previously complained to Health Canada about the time it takes to become licensed as well as the number of current applications waiting for approval.

For example, Aphria Inc. interim chief executive officer Irwin Simon said in January during a call with analysts that his company was still waiting for Health Canada to approve licensing for an expansion to one of its facilities in Leamington, Ont. despite submitting an application with the regulator in early 2018. The company received licensing for the facility in March.

“This is not a slam against Health Canada. It’s just we as an entire industry were not fully prepared for the [consumer] onslaught,” Simon said. “We have great pent-up demand; we are impatiently waiting, but we are waiting.”

Sherry Boodram, chief executive officer of cannabis consulting company CannDelta Inc. and a former Health Canada staffer, said the new licensing requirements will likely “hit the industry hard” and make it more difficult to get investors to commit to a cannabis-related project.

“Your business plan has to be sound and make sense,” she said in a phone interview with BNN Bloomberg. “It might deter some people who were thinking of getting into the industry, like the micro-cultivation type, because they need a lot of money up front.”

Health Canada said that since May 2017 it has licensed more than 129 new sites and counts more than 600,000 square metres of production space for legal cannabis – the equivalent of growing 1 million kilograms of legal pot in Canada annually, roughly the same amount consumed in the country.

Cannabis Canada is BNN Bloomberg’s in-depth series exploring the stunning formation of the entirely new – and controversial – Canadian recreational marijuana industry. Read more from the special series here and subscribe to our Cannabis Canada newsletter to have the latest marijuana news delivered directly to your inbox every day.

Source: https://www.bnnbloomberg.ca/game-changer-health-canada-changes-cannabis-licensing-process-1.1255720

Bougainville Ventures Inc $BOG.ca – 8 incredible facts about the booming US #marijuana industry #weed $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 11:00 AM on Wednesday, May 8th, 2019

SPONSOR:  Bougainville Ventures Inc (CSE: BOG) Converting irrigated farmland to greenhouse-equipped farmland. Bougainville does not “touch the plant” and only provides agricultural infrastructure as a landlord for licensed marijuana growers. Click here for more info.
BOG:CSE
—————————————

8 incredible facts about the booming US marijuana industry

  • The US marijuana industry is worth billions of dollars, and is showing no signs of slowing down.
  • Ten US states have legalized recreational marijuana use, and 33 have legalized medicinal use.

The marijuana industry is booming in the United States.

From the $52 billion in sales the industry posted to the 76% increase in cannabis jobs this year, there are plenty of statistics to show marijuana’s startling contributions to the US economy.

Marijuana initiatives have swept through state legislatures in recent years. Recreational marijuana use is legal in 10 US states, while medicinal marijuana is legal in 33. Illinois became the most recent state to weigh the topic when Gov. JB Pritzker introduced a bill to legalize the drug on Saturday.

Now, the industry is showing no signs of slowing down.

Read on for eight interesting facts about the US marijuana industry:

The marijuana industry could soon be worth more than the GDP of 9 US states

Associated Press

Marijuana Business Factbook estimates the legal-marijuana industry’s economic impact in the US was between $20 billion and $23 billion in 2017. It estimates the economic impact could reach as high as $77 billion by 2022.

Those numbers are comparable to the GDPs of Idaho and West Virginia, which were both a tick over $77 billion in 2018, according to the Bureau of Economic Analysis. And it’s worth more than the GDP of nine states, including Delaware, Alaska, and both North and South Dakota.

Cannabis employs five times as many Americans as coal

Associated Press

New Frontier Data, a cannabis market-research and data-analysis firm, estimates that the US cannabis industry employs at least 250,000 people. And those are just the jobs that are directly involved with handling marijuana plants – others in the industry are harder to quantify, a New Frontier economist told the Associated Press.

Compare that to the size of one of the staple blue-collar industries, coal mining, which employed 52,300 in 2018.

Another study estimated the marijuana industry would grow to at least 330,000 jobs by 2022, a higher number than the 268,000 employees at US steel and iron mills.

The median marijuana salary is 10% higher than the US median salary

AP Photo/Steven Senne

The median salary in the marijuana industry salary was $58,511 in 2018, while the median salary for US workers as a whole was $52,863, according to Glassdoor data. That’s a difference of 10.7%.

Investors poured $10 billion into the North American marijuana industry in 2018

Investors poured more than $10 billion into the North American marijuana industry in 2018, according to the Associated Press. That’s twice the total amount invested in the previous three years.

And experts project that number will shoot up to $16 billion this year.

Source: https://markets.businessinsider.com/news/stocks/weed-us-marijuana-industry-facts-2019-5-1028177375#the-marijuana-industry-could-soon-be-worth-more-than-the-gdp-of-9-us-states1

Marijuana Company of America’s $MCOA #hempSMART Subsidiary Plans Separate Listing on the Vienna Exchange $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:37 AM on Wednesday, May 8th, 2019
15233 mcoa
  • Announced that its wholly owned subsidiary, hempSMART, Ltd., is taking steps to list on the Vienna Stock Exchange (H Smart SARL),
  • Intends to raise sufficient capital to expedite the rollout of its hempSMART™ product line in Europe.

Escondido, California–(May 8, 2019) – MARIJUANA COMPANY OF AMERICA INC. (OTCQB: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce that its wholly owned subsidiary, hempSMART, Ltd., is taking steps to list on the Vienna Stock Exchange (H Smart SARL), with the intention of raising sufficient capital to expedite the rollout of its hempSMART™ product line in Europe.

Marijuana Company of America plans to sell a minority interest of hempSMART, Ltd., currently engaged in developing and marketing the hempSMART brand in Europe, for up to $10 million. The Company expects that all of the necessary steps to trade on the Vienna exchange will be completed by the beginning of the third quarter of 2019.

Once listed, hempSMART, Ltd. will be one of the first U.S.-based hemp-derived cannabidiol (CBD) companies to do an initial listing on a European exchange, as most cannabis and hemp public companies opt to list in Europe as a secondary listing. This is a result of the Company’s commitment to prioritizing its marketing efforts in the burgeoning European cannabis, hemp and CBD markets, with future plans to expand further.

“We are very excited to do an IPO of hempSMART, Ltd. on such a reputable European exchange,” said Don Steinberg, CEO of Marijuana Company of America. “This is a huge leap forward to obtain the necessary capital to bolster our European launch and become a top hemp brand in Europe. Europe’s cannabis and hemp markets are undergoing a critical phase in their growth and this is the optimum time to establish our brand as a leader. To date, we have exceeded expectations at our London event in March. In order to capitalize on this positive market momentum, we have planned two additional events in England, with two more following in Liverpool and Birmingham.”

hempSMART, Ltd. is expected to enter Portugal later this month, with future plans to extend further in France, Germany and Austria. hempSMART, Ltd. markets and sells the Company’s hemp and hemp-based personal wellness products, including the U.S.-patented hempSMART Brain™, an effective wellness product formulated with proprietary composition of natural ingredients and CBD to enhance brain function.

Jesus Quintero, CFO of MCOA, stated, “This offering on the Vienna exchange will help to strengthen the worldwide valuation for our hempSMART brand. We are highly optimistic about the prospects of this offering and the financial success of hempSMART.”

Ian Harvey, COO of hempSMART, Ltd., commented, “The U.S. patent issuance is indicative of the advances the Company achieved, and is a testament to the Company’s continued commitment to produce unique products of the highest quality, which distinguishes hempSMART as a leader of hemp-based CBD products.”

About Marijuana Company of America, Inc.
MCOA is a corporation that participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™,” which targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreational use; and (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward-Looking Statements
This news release contains “forward-looking statements” that are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

Contact:
[email protected]
888-777-4362

Corporate Communications Contact:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWire/MCOA

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/44536

Marijuana Company of America $MCOA Issues 2019 Shareholder Letter $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:30 AM on Tuesday, May 7th, 2019
15233 mcoa

Recent Company highlights include:

  • Global expansion with the debut of its hempSMART™ products in the UK
  • Established joint venture in California to operate a California cannabis delivery service named Viva Buds™
  • Details of the joint venture partnership with Global Hemp Group, completed a successful first harvest late in 2018 and is now in position to monetize its hemp biomass
  • Strategic partnership with MassRoots (OTCQB: MSRT) to promote its hempSMART CBD product line

Escondido, California–(May 7, 2019) – MARIJUANA COMPANY OF AMERICA INC. (OTCQB: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, today announces that on May 1, 2019, the Company mailed a letter to its shareholders to update them on recent developments and new business opportunities. In the letter, the Company provided a discussion on its two current acquisitions underway a review of its recent financial and operating performance and details of its new Viva Buds™ brand that will serve as a manufacturing, distribution and retail delivery service for cannabis products in the state of California.

Recent Company highlights include:

  • Marijuana Company of America’s global expansion with the debut of its hempSMART™ products in the UK
  • The Company’s established joint venture in California to operate a California cannabis delivery service named Viva Buds™
  • Details of the joint venture partnership with Global Hemp Group, which completed a successful first harvest late in 2018 and is now in position to monetize its hemp biomass
  • A strategic partnership with MassRoots (OTCQB: MSRT) to promote its hempSMART CBD product line

“Our shareholder letter addresses our hemp research and growth business expansion, and the two joint ventures we started with Global Hemp Group Inc. last year, which includes a working hemp farm in Oregon that just completed its successful first harvest in late 2018,” said Mr. Don Steinberg, Chairman and CEO of Marijuana Company of America. “We are confident to now be strategically positioned to drive more revenue and expand exponentially into new markets with our products and business growth methods.”

To read the letter to shareholders in full, please visit: http://marijuanacompanyofamerica.com/investor-relations/

About Marijuana Company of America Inc.
MCOA is a corporation that participates in: (1) product research and development of legal hemp-based consumer products under the brand name hempSMART™ which targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreational use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements

This news release contains “forward-looking statements” that are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

Contact:
[email protected]
888-777-4362

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWire/MCOA

Empower $CBDT.ca Announces Second Tranche Closing of Debenture and Unit Offerings and Announces Board of Director Changes $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 12:58 PM on Monday, May 6th, 2019
Epw logo1
  • “The strong support of our financing round demonstrates that shareholders and investors have faith in our ability to execute on initiatives, as we establish vertical integration connecting patient efficacy…,” stated Steven McAuley, Empower Chairman and CEO.

VANCOUVER, May 3, 2019 – EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (“Empower” or the “Company“), a growth oriented and diversified medical cannabis company, is pleased to announce the closing of the second tranche of a non-brokered private placement of unsecured convertible debentures (the “Debentures“), pursuant to which it has issued Debentures in the aggregate principal amount of $207,270, and the second tranche of a non-brokered private placement of an aggregate of 5,762,500 units of the Company (each, a Unit“) at a price of $0.10 per Unit for gross proceeds of $576,250, for combined total proceeds of $783,520 (together, the “Offerings“).

The proceeds of the Offerings are expected to be used by the Company for the completion of strategic acquisitions and for general working capital and corporate purposes.

“The strong support of our financing round demonstrates that shareholders and investors have faith in our ability to execute on initiatives, as we establish vertical integration connecting patient efficacy in our clinics with a diverse CBD product strategy and the backing of the science of extraction, all driven by data and analysis,” stated Steven McAuley, Empower Chairman and CEO.

RECENT HIGHLIGHTS

  • Intention to Launch CBD Extraction Facility The Company intends to open a fully functioning hemp-based CBD extraction facility in greater Portland, Oregon in Q2 2019, with the first extraction system expected to have the capacity to produce 6,000 kilograms of extracted product per year. The 5,000 sq. ft. facility in Sandy, OR has now been secured through a 5 year lease agreement and preparations are underway to begin licensing and permit requirements to commence operations in 2019.

  • Acquisition of Sun Valley Clinics Empower has completed the acquisition of the business of Sun Valley Certification Clinics Holdings LLC (“Sun Valley“), including its interests in certain affiliates, by way of a share acquisition. Sun Valley operates a network of professional medical cannabis and pain management practices, with five clinics in Arizona, one clinic in Las Vegas, a tele-medicine platform serving California, and a fully developed franchise business model for the domestic cannabis industry. The current Sun Valley clinic locations are as follows:

    4218 W Dunlap Ave, Phoenix, AZ
    12801 W Bell Rd #145, Surprise, AZ
    4015 E Bell Rd #130, Phoenix, AZ
    2011 E University Dr, Mesa, AZ
    7074 E Speedway Blvd, Tucson, AZ
    2550 S Rainbow Blvd, Las Vegas, NV
  • Focus on CBD Product Sales Empower has commenced selling its proprietary line of CBD-based products called SOLLIEVO, through its network of company-owned clinics in the United States. Empower’s patient base and customers are expected to benefit from access to high margin derivative products, including CBD lotion, tinctures, spectrum oils, capsules, lozenges, patches, e-drinks, topical lotions, gel caps, hemp extract drops and pet elixir hemp extract drops. Patients and customers will be able to access Empower’s home delivery and e-commerce platform.

  • CBD Market Demand The passing in the United States of the US$867 billion Agriculture Improvement Act (the “Farm Bill“) has legalized hemp and hemp-based products. This has created an opportunity for the production and sale of a variety of CBD-based products that can provide genuine help and effective relief to millions of people suffering from a variety of qualifying conditions. Recent reports and studies indicate the approval of the Farm Bill could create a US$20 billion industry by 2022.

  • Increased Patient Access With a rapidly expanding company-owned clinic network and significant expansion opportunity assuming the successful acquisition of the Sun Valley franchise model, Empower anticipates it will grow its total patient list substantially in the years ahead. This is expected to provide greater opportunity for treatment analysis using artificial intelligence (AI).

  • Market Leading Technology Empower utilizes a market-leading patient electronic management and POS system that is HIPAA compliant and provides insight to patient care. The Company supports remote patients using its tele-medicine portal, enabling patients who are unable to come to a location to benefit from a doctor consultation.

The Debentures bear interest at the rate of 6.0% per annum and mature on May 3, 2020, being 12 months from the closing of the Offerings (the “Closing“). The Debentures are convertible, at the option of the Company or the holder, into units of the Company (each, a “Debenture Unit“) at a conversion price of $0.11 per Debenture Unit, with each Debenture Unit consisting of one common share in the capital of the Company (each, a “Share“) and one share purchase warrant (each, a “Warrant“), with each Warrant exercisable into one Share (each, a “Warrant Share“) at a price of $0.16 per Warrant Share for a period of two years following the Closing, provided that the Company will have the right to accelerate the expiry date of the Warrants in the event that the closing sale price of the Shares on the Canadian Securities Exchange (the “CSE“) (or such other stock exchange as the Shares are then principally traded) is greater than $0.40 per Share for a period of 10 consecutive trading days at any time after the issuance of the Warrants.

Each Unit is comprised of one Share and one Warrant, with each Warrant exercisable into one Warrant Share at an exercise price of $0.16 per Warrant Share for a period of two years following the Closing, provided that the Company will have the right to accelerate the expiry date of the Warrants in the event that the closing sale price of the Shares on the CSE (or such other stock exchange as the Shares are then principally traded) is greater than $0.40 per Share for a period of 10 consecutive trading days at any time after the issuance of the Warrants. 

The Debentures and the Units, and the underlying Shares, Warrants and Warrant Shares (collectively, the “Securities“), are subject to restrictions on resale under applicable Canadian securities laws for a period of four months and one day from the closing of the Offerings. None of the Securities have been or will be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would require registration or otherwise be unlawful.

The Company also announces that Emily Davis has resigned as a Director and member of the effective immediately. The Company thanks Ms. Davis for her valuable contributions.

In addition, the Company announces that Dustin Klein has been appointed as a Director in conjunction with the previously announced closing of the Sun Valley acquisition.

ABOUT EMPOWER

Empower is a leading multi-state operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative physician recommended treatment options. It is expected that Empower’s proprietary product line “Sollievo” will offer patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based products in its clinics, online and at major retailers. With over 165,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine, and an expanded product development strategy, Empower is undertaking new growth initiatives to be positioned as a vertically integrated, diverse, market-leading service provider for complex patient requirements in 2019 and beyond.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the proposed acquisition of Sun Valley; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the expected location of the proposed CBD extraction facility; the effectiveness of the extraction technology; the size of the leased facility; the expected benefits for Empower’s patient base and customers; access to Empower’s home delivery and e-commerce platform; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including that: the proposed acquisitions and partnerships, including the Sun Valley and Aibeida transactions, may not be completed on the terms expected or at all; that the Company may not open a hemp-based CBD extraction facility; that the hemp-based CBD extraction facility may not be fully operation by Q2 2019 if at all; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/06/c9104.html

Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-6274Copyright CNW Group 2019

North Bud Farms Inc. $NBUD.ca – More Canadians smoking up and buying it from legal sources $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 12:25 PM on Thursday, May 2nd, 2019

SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE

—————

More Canadians smoking up and buying it from legal sources

  • A new report on cannabis use in Canada shows how many have tried it for the first time, how many smoke daily, and how many think it is okay to drive within two hours of smoking up.
  • It said 5.3-million Canadians or 18 per cent over the age of 15 admitted to using cannabis within the past three months
  • That is an increase from 14 per cent during the same period last year before legal recreational use.

By Adelle Loiselle

May 2, 2019

A new report on cannabis use in Canada shows how many have tried it for the first time, how many smoke daily, and how many think it is okay to drive within two hours of smoking up.

Statistics Canada released the report detailing use in the first quarter of 2019 Thursday.

It said 5.3-million Canadians or 18 per cent over the age of 15 admitted to using cannabis within the past three months. That is an increase from 14 per cent during the same period last year before legal recreational use. In Ontario, one in five residents used in the first quarter of 2019 compared to 14 per cent during that period in 2018.

An increase among men aged 45 to 64 partially explains the rise. It went up to 22 per cent from 16 per cent a year ago, while use among women remained stagnant at 13 per cent.

Some 646,000 people admitted to trying it for the first time, while others had used it in the past but tried it again after abstaining for years. Older users accounted for a third of all people who sampled for the first time.

The percentage of daily users did not change from 2018, but there were more weekly and occasional consumers.

The report also showed that more people are buying their cannabis from legal sources. Statistics Canada says 47 per cent of users obtained solely from legitimate sources, like the Ontario Cannabis Store or legal retail marijuana stores, while 38 per cent got it illegally, down from 51 per cent last year. The rest used a mix of legal and illegal sources.

Cannabis use and driving still present a safety concern. The agency said half of Canadians believe it is safe to drive after three hours of using cannabis, but 15 per cent believed it was safe to get behind the wheel less than two hours afterwards. Many of those who drove earlier also said they had been passengers in a vehicle where the driver consumed cannabis within two hours of driving.

More than half a million Canadians also confessed to either using cannabis right before going to work or while on the job. About 27 per cent of those people were daily users.

Source: https://blackburnnews.com/windsor/windsor-news/2019/05/02/canadian-smoking-buying-legal-sources/

Empower Clinics $CBDT.ca Announces Closing of Acquisition of Sun Valley Clinics $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca $BUZZ.ca

Posted by AGORACOM-JC at 3:38 PM on Wednesday, May 1st, 2019
  • Completed the acquisition of Sun Valley Certification Clinics Holdings LLC
  • Operates a network of professional medical cannabis and pain management practices, with five clinics in Arizona, one clinic in Las Vegas, a tele-medicine platform serving California, and a fully developed franchise business model for the domestic cannabis industry
  • Will expand Empower’s multi-state operations, having a combined patient count of 165,000 patients, in Washington, Oregon, Illinois, Arizona, Nevada and California

VANCOUVER, May 1, 2019 - EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (“Empower” or the “Company“) is pleased to announce that, pursuant to the terms of a membership interest purchase agreement dated April 30, 2019, it has completed the acquisition of Sun Valley Certification Clinics Holdings LLC (“Sun Valley“) from Andrea Klein and Dustin Klein (together, the “Vendors“) and a minority shareholder, through its wholly-owned subsidiary, Empower Healthcare Assets Inc. (“Empower Health“), for cash and share consideration having an aggregate value of US$3,835,000 (CAD$5,160,376), effective as of April 30, 2019 (the “Transaction“). Sun Valley operates a network of professional medical cannabis and pain management practices, with five clinics in Arizona, one clinic in Las Vegas, a tele-medicine platform serving California, and a fully developed franchise business model for the domestic cannabis industry.

In connection with the Transaction, Empower also acquired the 30% minority membership interests held by Green Global Properties Inc. (“Green Global“), a subsidiary of Aura Health Inc. (CSE: BUZZ), in three partially-owned subsidiaries of Sun Valley, operating clinics in Mesa and Phoenix, Arizona, and Las Vegas, Nevada, such that Empower now indirectly owns all of the membership interests in each of such subsidiaries (the “GG Acquisition“).

Over the past five years, Dustin and Andrea have built one of the most reputable and organized clinic networks in Arizona, developing a patient list of more than 45,000 unique patients, and have performed over 61,000 certifications to date. Sun Valley supports its patients with a dynamic dedicated team consisting of 52 staff, including 30 physicians.

“The acquisition of the Sun Valley clinic group has fundamentally changed the direction and growth prospects for Empower,” said Steven McAuley, Empower’s Chairman & CEO. “We have repositioned Empower as a vertically integrated global health and wellness company, helping consumers access products and specialized medical care for serious qualifying conditions. Having Dustin and Andrea Klein join me in leadership to rapidly expand Empower’s clinic and distribution network across the United States is a major step toward our ambitious objectives.”

“This acquisition is a testament to the hard work and dedication our team has provided to our community for the past five years and I look forward to being a valuable resource to the Company and on the board of directors,” said Dustin Klein, Sun Valley Co-founder.

Andrea Klein, Sun Valley Co-founder, stated, “I am delighted with our acquisition by Empower Clinics! It is the evolution of our dream, to positively affect the lives of patients across the country, and to become an adaptive and strategic organization that can harness the phenomenal and exciting growth of the cannabis industry. Steve’s vision for Empower is inspiring, and I am eager to bring our team together with his vision and grow into a dominating national brand that leads the way in patient care, employee satisfaction, and potential shareholder profitability!”

The Transaction is expected to create one of the largest clinic groups in the medical cannabis sector in the United States, which, together with Empower’s existing medical cannabis clinics, will expand Empower’s multi-state operations, having a combined patient count of 165,000 patients, in Washington, Oregon, Illinois, Arizona, Nevada and California, and the potential to rapidly expand the clinic network via the Sun Valley franchise program.

TRANSACTION HIGHLIGHTS

  • Improved Capital Markets Profile Empower is diversifying its business model to become a vertically integrated operator in the global cannabis sector with a focus on patient care, CBD product distribution, research & development and CBD product extraction. The Company believes this will appeal to a broader base of shareholders and investors and provide greater access to capital and improved trading liquidity.

  • Increased Patient Access With a rapidly expanding company-owned clinic network and significant expansion opportunity through the Sun Valley franchise model, Empower anticipates it will grow its total patient list substantially in the years ahead. This is expected to provide greater opportunity for treatment analysis using artificial intelligence (AI), validating the Company as a leader in understanding the efficacy of cannabis-related therapies.

  • Focus on CBD Product Sales Empower’s patient base and customers are expected to benefit from access to high margin derivative products, including CBD lotion, tinctures, spectrum oils, capsules, lozenges, patches, e-drinks, topical lotions, gel caps, hemp extract drops and pet elixir hemp extract drops. Patients and customers will be able to access Empower’s customer service, home delivery and e-commerce platform.

  • Market Leading Technology Empower utilizes a market-leading patient electronic management and POS system that is HIPAA compliant and provides deep insight to patient care. The Company supports remote patients using its tele-medicine portal, enabling patients who do not live near one of its clinic locations, or are disabled or unable to come to a location, to still benefit from a doctor consultation.

  • The Sun Valley Clinic Locations

4218 W Dunlap Ave, Phoenix, AZ
12801 W Bell Rd #145, Surprise, AZ
4015 E Bell Rd #130, Phoenix, AZ
2011 E University Dr, Mesa, AZ
7074 E Speedway Blvd, Tucson, AZ
2550 S Rainbow Blvd, Las Vegas, NV

In connection with the closing of the Transaction (the “Closing“), Empower: (i) paid the Vendors an aggregate cash payment of US$775,000 (CAD$1,042,840), of which US$150,000 (CAD$201,840) is being heldback by Empower, half of which is to be released six months from the date of Closing and the other half of which is to be release twelve months from the date of Closing and (ii) issued the Vendors an aggregate of 22,058,823 common shares in the capital of the Company (each a “Share“) at a deemed price of US$0.136 (CAD$0.183) per Share, representing the average daily closing price of the Shares on the Canadian Securities Exchange for the 10-day trading period ended April 26, 2019. 14,705,882 of the Shares will be held in escrow by Odyssey Trust Company pursuant to an escrow agreement dated April 30, 2019, and will vest in quarterly installments over 36 months from the date of the Closing. The Company also paid US$12,318 (CAD$16,575) and issued 350,602 Shares to a minority shareholder of one of the Sun Valley subsidiaries in order to acquire her minority interest therein.

Each of the Vendors have also entered into employment agreements with an affiliate of the Company pursuant to which Dustin Klein will serve as the Vice President of Business Development, and Andrea Klein will serve as the Vice President of Operations. In these roles, they will continue to provide their extensive industry knowledge and expertise to Sun Valley and the Company. In addition, Dustin Klein has been appointed as a director of the Company, effective as of the Closing.

In consideration for the GG Acquisition, Empower Health issued Green Global a promissory note in the principal amount of US$125,000, which bears interest at the rate of 4.0% per annum and has a maturity date of July 31, 2019.

None of the Shares to be issued in connection with the Transaction will be registered under the United States Securities Act of 1933, as amended (the “1933 Act“), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons” (as such term is defined in Regulation S under the 1933 Act), absent registration or an applicable exemption from such registration requirements.

ABOUT EMPOWER

Empower is a leading multi-state operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative physician recommended treatment options. It is expected that Empower’s proprietary product line “Sollievo” will offer patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based products in its clinics, online and at major retailers. With over 165,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine, and an expanded product development strategy, Empower is undertaking new growth initiatives to be positioned as a vertically integrated, diverse, market-leading service provider for complex patient requirements in 2019 and beyond.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the direction and growth prospects of the Company, the expansion of the company’s clinic and distribution network, the expected effect of the Vendors in their new roles with the Company, the effect on the lives of patients, the growth into a national brand, the effect of the Transaction, the diversification of the Company’s business model, the potential appeal to shareholders, the growth of the Company’s patient list and the effect thereof, the expected benefits for the company’s patient base and customers, the release of the cash consideration, the release of Shares being held in escrow in connection with the Transaction and statements regarding the Company’s proprietary product line “Sollievo”. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including that the Company may not be able to expand, that the Transaction may not have the expected results, and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/01/c3033.html

Investors: Steve Low, Boom Capital Markets, 647-620-5101; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-6274; Investors: Steven McAuley, CEO, [email protected], 604-789-2146Copyright CNW Group 2019

INTERVIEW: Bougainville $BOG.ca Accelerates Vertical Integration With 5 Marijuana Locations In Alberta + Hemp CBD In Oregon $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 6:09 PM on Tuesday, April 23rd, 2019

Bougainville (BOG:CSE) has laid a strong foundation for growth – literally – by establishing itself as the landlord to smaller USA marijuana growers that needed a turnkey solution.  With it’s first tenant moving into 10,000 square feet this June in Washington State and adding another 20,000 thereafter, the Company is confidently branching out to become a vertically integrated producer and retailer in Canada. 

Most companies would be happy with two lines of business but BOG is adding a 3rd line via Hemp CBD production in Oregon.

Watch this video to learn more about Bougainville Ventures (BOG:CSE).

North Bud Farms Inc. $NBUD.ca – #Pot stocks are soaring and the #cannabis industry is poised for ‘tons of growth’ $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 12:00 PM on Tuesday, April 23rd, 2019

SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE

—————

Pot stocks are soaring and the cannabis industry is poised for ‘tons of growth’

  • Publicly traded cannabis companies have reported strong sales since Canada legalized pot last October and several US states voted to approve recreational and medical marijuana use
  • Cannabis has also gone mainstream thanks to big investments and partnerships between marijuana sellers and blue chip consumer companies.

New York (CNN Business) For decades, though nobody was really sure why, April 20 has been the unofficial holiday for marijuana users and a joke by and about them. Now, though, it’s also a reminder of how quickly marijuana is moving from illegal and a joke to a multi-billion dollar legal business — and a good time for us to take another look at how well cannabis stocks have been doing. Publicly traded cannabis companies have reported strong sales since Canada legalized pot last October and several US states voted to approve recreational and medical marijuana use. Cannabis has also gone mainstream thanks to big investments and partnerships between marijuana sellers and blue chip consumer companies. Corona owner Constellation Brands (STZ) has a more than 35% stake in Canopy Growth (CGC), a Canadian cannabis company that intends to take a bigger step into the United States with plans to buy American cannabis firm Acreage Holdings. Constellation also disclosed Thursday it may eventually boost its stake in Canopy to 50%.   Pot stocks may be a bubble that needs to burst Marlboro-owner Altria (MO) invested $1.8 billion in cannabis producer Cronos Group (CRON). And Tilray (TLRY) is working on cannabis-infused drinks with Budweiser owner AB InBev (BUD). But many of these stocks have soared this year already — Cronos is up nearly 60% so far while Canopy has gained 70% — leading to questions about whether this is just a speculative mania like tulips and dot-com companies.

Bubble or bargain?

“This business is still in its infancy. It’s like investing in alcohol post-Prohibition. There will be tons of growth,” said Dan Ahrens, chief operating officer with investment firm AdvisorShares. “But there are going to be home runs and there will be lots of strikeouts.” Ahrens thinks that investors need to be patient and selective. But he believes they will be rewarded — that is, if they wind up picking the winners. “These are new, up and coming companies. There is going to be volatility so you have to be selective,” Ahrens said, adding that he favors companies that haven’t already shot up because they’ve done big deals like Canopy and Cronos have.   Ex-NFL player Tiki Barber now invests in pot AdvisorShares just launched the Pure Cannabis ETF (YOLO), an actively managed fund that invests in cannabis stocks. Some of its top holdings are Canadian cannabis companies CannTrust (CTST), Aphria (APHA) and Hexo (HEXO).   Canopy Growth co-CEO: Product opportunity is ‘substantial’05:27 Rob Almeida, global investment strategist with MFS Investment Management, said investors may be getting ahead of themselves. He’s worried that cannabis stocks are going to turn out to be an investing fad like 3D printing and blockchain companies. “Cannabis is not going to have parabolic growth,” Almeida told CNN Business. “There is a lot of hope and enthusiasm.”

Cannabis prices are falling

One cause for concern: Now that more states are legalizing marijuana use, prices are dropping as competition has increased. Research firm BDS Analytics, which calculates a consumer price index for the cannabis industry in the United States, recently reported that overall prices in February for products such as ingestibles, topical creams, vaporizers and vape pens and pre-rolled joints, fell 2.7% from February of 2018. Prices were down nearly 2% from the prior month. Many of the publicly traded cannabis companies have been reporting a drop in the retail price in Canada since legalization last October as well. Aphria, for example, reported sales this week that missed forecasts. Shares plunged nearly 15% on the news. But the stock is still up more than 40% so far in 2019.

More deals likely on the way

A lot of the excitement has to do with expectations of more mergers and partnerships. Aurora Cannabis (ACB), a Canadian company whose stock has soared 80% this year, recently announced that it was adding legendary investor and deal maker Nelson Peltz as an adviser. That’s led to speculation that Peltz may help Aurora team up with a consumer products or healthcare company. Tilray, for example, also has a strategic relationship with generic drug maker Sandoz, a subisidiary of Novartis (NVS). So other cannabis firms may look to team up with Big Pharma.   Canopy’s plans to buy Acreage could lead to another wave of consolidation too. Matt Hawkins, managing principal at Cresco Capital Partners and an investor in Acreage, said in an email to CNN Business that “this is the moment the cannabis sector knew was coming — consolidation.”   Hawkins added that the deal “will lead to a rush of cannabis companies merging in order to compete with Canopy/Acreage” and that “it’s now going to be very hard for early start-ups to enter the space and compete with the growing/emerging conglomerates.” In other words, there’s another sign that cannabis is going legit: It’s starting to function just like any other major consumer industry.   Source: https://www.cnn.com/2019/04/19/investing/cannabis-stocks-420/index.html

North Bud Farms Inc. $NBUD.ca – How to Value a #Pot #Cannabis Stock $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 11:32 AM on Thursday, April 18th, 2019

SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Click Here For More Information

NBUD: CSE

—————

How to Value a Pot Stock

By Tara Lachapelle and Sarah Halzack

While cannabis investors are distracted by seeds and crop yields, corporations with M&A in mind see a more lucrative future in brand-building and retail.

Cannabis growers have hardly any revenue and their product is still illegal in their most desirable market, the U.S. That’s not stopping investors and corporate giants from spending billions of dollars to take stakes in these companies. They obviously see growth potential. And yet the question remains, how do you even value a pot business? 

Altria Group Inc., the U.S. tobacco leader and maker of Marlboro cigarettes, announced in December that it was buying 45 percent of Cronos Group Inc., one of Canada’s growing number of cannabis producers and among the industry’s high-flying stocks. The $1.8 billion transaction left us wondering: How did Altria determine that price? After all, in the period before the deal, Cronos generated sales of less than $4 million – no, that’s not a typo – and certainly no profits. Recreational pot had only just become legal in Canada two months earlier. Altria, a $105 billion market-cap company that rarely does splashy deals, placed immense value on a barely existent business in a nascent market.

The dynamics were the same when Constellation Brands Inc., a beer and liquor conglomerate, spent $3.8 billion to increase its stake in Canopy Growth Corp. earlier in 2018. Canopy’s CEO has said he wants it to become the Google of pot â€“ but he’ll need to add a few more digits to its sales figures. 

Seeing Green

The projected growth of the worldwide cannabis market has some investors pouring money into newcomer companies with tiny revenue and no profits

Source: Arcview Market Research, BDS Analytics

It’s a tricky thing to gauge the worth of assets that will potentially be highly valuable down the road – but are difficult to quantify just yet. Looking at other industries where this has been the case is helpful. Even if their businesses aren’t perfect comparisons, the method of valuing them can be instructive. 

Take the natural-resources space, where the focus is often on non-financial metrics. They include production capacity and tangible assets, such as proved oil reserves – which is to say, how much fuel a producer can likely pump from their land. It can be argued that this is similar to how individual investors already have been gauging cannabis companies, dazzled by how many kilograms can be produced and how many acres of greenhouse they have.

But the downside to this approach for cannabis is that it puts too much emphasis on supply-chain processes that may become commoditized, and a rudimentary focus on capacity doesn’t capture how the early movers in this market can differentiate themselves. The industry’s novelty also distracts from what can be a challenging business from an operational standpoint. For example, Aphria Inc.’s share price increased more than elevenfold over the last five years, but in its latest quarter the business was hamstrung by supply shortages and packaging issues. 

A better comparison for cannabis may be the biotechnology space. Deals for drug developers involve big, risky bets on future potential blockbusters. These products may not generate revenue yet, but they aim to address very specific markets and are expected to have an economic moat that wards off competition. For pharmaceuticals, that moat comes from patent exclusivity that prevents copycat versions of a therapy. In some ways, this is what the more advanced cannabis companies are looking to accomplish. They won’t have patents in the same way, but they do aim to create intellectual property and specialized brands that appeal to certain types of customers. And they want to be first to form those customer relationships.

Remember, this market will be far more expansive than simply selling a box of joints. There’s an opportunity to create all sorts of consumer products, and the marketing can vary widely – from wellness drinks and beauty items infused with cannabidiol, or CBD (the part of cannabis that doesn’t deliver a high), to “sin” products like marijuana-infused edibles, or something more akin to having a glass of wine.

Taking Off

As the recreational cannabis market surpasses the medical one, it will become increasingly important for companies to create compelling brands

Source: Arcview Market Research, BDS Analytics

Look at it this way: Altria doesn’t own tobacco farms. It owns high-margin brands that source from tobacco growers. So when it’s studying the future of marijuana, it’s not looking solely at production. It’s looking for unique brands that can be scaled up by a team with the necessary know-how. In the case of Cronos, CEO Mike Gorenstein said on the last earnings call that the company is trying to differentiate itself with pre-rolled joints, adding that innovation around branding and efficiency will be “a bigger differentiator than just cultivation.”

Knowing the important role that brand-building will play in the next phase of the cannabis industry’s growth story, it’s useful to study these companies’ senior management teams and look for branding and retail pedigree. It’s a good sign that Cronos’s head of marketing has had stints at PepsiCo Inc. and Mondelez International Inc., and that Tilray Inc. has a one-time Starbucks Corp. executive running its retail strategy.

Green Growth Brands Inc., based in Ohio and Ontario, has a deep bench of such leaders: Its CEO is Peter Horvath, a former executive at American Eagle Outfitters Inc., Victoria’s Secret and DSW. His key deputies come from the likes of Abercrombie & Fitch Inc. and Bath & Body Works. They are rightly emphasizing that retail expertise is a point of distinction and an advantage as they develop targeted brands such as Green Lily, aimed at women, and Camp, aimed at active, outdoorsy types. This brand-centricity seems to be paying off: Even though Green Growth doesn’t have as large a market capitalization as the Canada-based players, it recently scored a partnership with Simon Property Group Inc. to open more than 100 CBD stores in the mall giant’s shopping centers, and its CBD products will be sold in 96 DSW locations.

That U.S. footprint might do it good down the road, as wider marijuana legalization seems likely. While much of the focus these days is around the promise of the Canadian market, it’s important not to let that obscure what should be the cannabis world’s real end game. 

Sizing Up The U.S. Prize

California alone has a larger population than Canada, illustrating why the U.S. remains such a tantalizing opportunity for the cannabis industry

Source: Statistics Canada, U.S. Census Bureau

And, in general, the Canadian companies that have received such bountiful investor buzz are at something of a disadvantage on the branding front, notes Bethany Gomez, a cannabis industry analyst at Brightfield Group. Because of strict rules in Canada regarding logo size and other packaging details for currently available cannabis products, they are simply limited in how distinctive they can make their presentation.

Wherever it’s sold, if the cannabis business is to grow as big as the industry’s bulls hope, it is going to have to successfully court non-users and infrequent users. That’s where newer innovations, such as edibles and beauty items, may be more important than smokeable products. 

Not Quite Cannabis Crazy

In U.S. markets that have legalized recreational marijuana, many people are still not consuming cannabis, underscoring the opportunity to grow addressable market

Source: BDS Analytics Consumer Insights

The companies that become the breakout stars in the legal cannabis era will be the ones that have a vision for how to create demand for such goods, whether through curiosity-inducing product, a great in-store experience or alluring marketing. These capabilities â€“ not merely spreading more seeds in soil – should be a critical part of valuing the pot pioneers.

Source: https://www.bloomberg.com/opinion/articles/2019-04-18/altria-shows-there-s-a-better-way-to-value-cannabis-stocks